Abstract:OBJECTIVE:To produce an erythrocytic stage chimeric protein of Plasmodium berghei in Pichia pastoris and evaluate its immunogenicity.METHODS:The DNA sequences of AMA1 (III) and MSP1-19 from P. berghei homologous to the corresponding sequences of P. falciparum chimeric antigen 2.9 (PfCP-2.9) were fused to generate a chimeric gene, designated as PbCP-2.9. The resulting gene was redesigned using Pichia preferential coden usage and expressed in P. pastoris in the secreted form. The recombinant protein was purified by Ni-NTA affinity chromatography. Three groups each with 10 BALB/c mice were immunized subcutaneously with 20 microg of purified PbCP-2.9 antigen formulated in Freund's adjuvant, Montanide ISA720 and Montanide IMS 1312, respectively. Three control groups each with 10 mice received only adjuvants emulsified with PBS. All the mice received three immunizations at 2-week intervals with the same dose of antigen. Serum samples were collected at pre-immunization and one week after each immunization, and were analyzed for specific antibodies by ELISA and reaction with natural P. berghei proteins by IFAT.RESULTS:The PbCP-2.9 antigen with Mr 26400 was successfully expressed in P. pastoris in secreted form. The recombinant protein can be recognized by the serum against blood stage parasites of P. berghei. High antibody responses were detected in all three PbCP-2.9-immune groups of mice by ELISA. However, mice immunized with PbCP-2.9 antigen in Freund's adjuvant produced higher antibody titers than those with PbCP-2.9 antigen in Montanide ISA 206 and Montanide IMS 1312 adjuvants. The mean antibody titer in Freund's adjuvant was 6.9-fold higher than in Montanide ISA 206 adjuvant and 5.6-fold higher than in Montanide IMS 1312 adjuvant after the second immunization (F=81.06, P< 0.01). In addition, after the third immunization the mean antibody titer in Freund's adjuvant was 3.7-fold higher than in Montanide ISA 206 adjuvant and 3.3-fold higher than in Montanide IMS 1312 adjuvant (F=13.29, P< 0.01). The results from IFAT assay demonstrated that the immune sera recognized the surface proteins of P. berghei parasites.CONCLUSION:The coden-optimized PbCP-2.9 gene has been constructed and expressed in P. pastoris. The chimeric antigen is highly immunogenic in mice and the immune sera can interact with natural proteins of P. berghei parasite.

[Evaluation of Immunogenicity and Protection Efficacy of the Recombinant Hypoxanthine-Guanine-xanthine of Plasmodium Falciparum in Mice].

A Long-Lasting Protective Immunity Against Chronic Toxoplasmosis in Mice Induced by Recombinant Rhoptry Proteins Encapsulated in Poly (Lactide-Co-glycolide) Microparticles.

Establishment and Evaluation of Colloid Gold Labeled Immunochromatographic Strip Test for Rapid Diagnosis of Falciparum Malaria Based on Capturing Antigen Histidine-Rich Protein II of Plasmodiun Falciparum

[Construction and Expression of Plasmodium Berghei Chimeric Protein in Pichia Pastoris and Its Immunogenicity in Mice].

Immunogenicity of Plasmodium falciparum chimeric protein PfCP-2.9 in various strains of mice

The Production and Immunogenicity of the Functional Fragment of Plasmodium Falciparum Merozoite Surface Protein 3

Construction of Transgenic Plasmodium Berghei As a Model for Evaluation of Blood-Stage Vaccine Candidate of Plasmodium Falciparum Chimeric Protein 2.9.

Ginseng Stem-and-Leaf Saponin (GSLS)-Enhanced Protective Immune Responses Induced by Toxoplasma gondii Heat Shocked Protein 70 (HSP70) Against Toxoplasmosis in Mice

Effect of Ginsenoside Rg1 on Immune Efficacy of P30 Fusion Protein of Toxoplasma Gondii in Mice

Immunogenicity Analysis of the Recombinant Plasmodium falciparum Surface-Related Antigen in Mice

IMMUNE RESPONSES OF MICE VACCINATED WITH RECOMBINANTS CODED DIFFERENT STAGE GENES FROM FCC 1/HN STRAIN OF PLASMODIUM FALCIPARUM

CELL-MEDIATED AND HUMORAL IMMUNE RESPONSES IN MICE INDUCED BY A MALARIA DNA VACCINE FROM A HYBRID GENE OF ANTIGEN FOR PLASMODIUM FALCIPARUM

Optimization of an in vivo model to study immunity to Plasmodium falciparum pre-erythrocytic stages

PRELIMINARY STUDIES ON MOUSE PLASMODIUM YOELII MODEL FOR THE EVALUATION OF A MULTI-EPITOPE VACCINE CANDIDATE OF PLASMODIUM FALCIPARUM

Infectivity and Screening of Anti-piperaquine Genes in Mice Infected with Piperaquine-Sensitive and Piperaquine-Resistant Plasmodium berghei

A New Malaria Antigen Produces Partial Protection Against Plasmodium Yoelii Challenge

Detection of lymphocyte proliferation stimulated by HGXPRT protein of Plasmodium falciparum

Cd4(+) T-Cell- and Gamma Interferon-Dependent Protection Against Murine Malaria by Immunization with Linear Synthetic Peptides from A Plasmodium Yoelii 17-Kilodalton Hepatocyte Erythrocyte Protein

Establishment of a genetically attenuated strain of Plasmodium berghei ANKA and its immune protective effect

[Expression and Immunogenicity Evaluation of Ectodomain and Subdomains of Plasmodium Berghei Apical Membrane Antigen 1].

Humoral Immune Responses in Mice to the Recombinant Expressed Protein and the Nucleic Acid Vaccine of Circumsporozoite Protein Gene of Plasmodium Falciparum